

Petros Perros

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1110618/publications.pdf>

Version: 2024-02-01

191
papers

11,210
citations

34105

52
h-index

31849

101
g-index

195
all docs

195
docs citations

195
times ranked

7683
citing authors

#	ARTICLE	IF	CITATIONS
1	The enigma of persistent symptoms in hypothyroid patients treated with levothyroxine: A narrative review. <i>Clinical Endocrinology</i> , 2023, 98, 461-468.	2.4	33
2	Use of thyroid hormone in hypothyroid patients and euthyroid subjects in Spain: A THESIS* questionnaire survey. <i>Endocrinología, Diabetes Y Nutrición</i> , 2022, 69, 520-529.	0.3	11
3	Use of thyroid hormones in hypothyroid and euthyroid patients: a 2020 THESIS questionnaire survey of members of the Hellenic Endocrine Society.. <i>Hormones</i> , 2022, 21, 103-111.	1.9	13
4	Real-life practice of thyroid hormone use in hypothyroid and euthyroid patients: A detailed view from the THESIS questionnaire survey in France. <i>Annales D'Endocrinologie</i> , 2022, 83, 27-34.	1.4	11
5	Primary hypothyroidism and quality of life. <i>Nature Reviews Endocrinology</i> , 2022, 18, 230-242.	9.6	55
6	Use of thyroid hormones in hypothyroid and euthyroid patients: a THESIS* survey of Belgian specialists *THESIS: treatment of hypothyroidism in Europe by specialists: an international survey. <i>Thyroid Research</i> , 2022, 15, 3.	1.5	12
7	Health care access of thyroid disease patients in Serbia during the COVID-19 pandemic. <i>Journal of Endocrinological Investigation</i> , 2022, , 1.	3.3	0
8	Postradioiodine Graves' management: The PRAGMA study. <i>Clinical Endocrinology</i> , 2022, 97, 664-675.	2.4	3
9	Use of thyroid hormones in hypothyroid and euthyroid patients: a 2020 THESIS questionnaire survey of members of the Czech Society of Endocrinology. <i>BMC Endocrine Disorders</i> , 2022, 22, 117.	2.2	10
10	A Questionnaire Survey of German Thyroidologists on the Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients: The THESIS (Treatment of Hypothyroidism in Europe by Specialists: An) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 38 577-586.	1.2	12
11	Enhanced Well-Being Associated with Thyrotoxicosis: A Neglected Effect of Thyroid Hormones?. <i>International Journal of Endocrinology and Metabolism</i> , 2022, 20, .	1.0	1
12	Antithyroid drugs in Gravesâ€™ hyperthyroidism: differences between âœœblock and replaceâ€ and âœœtitrationâ€ regimes in frequency of euthyroidism and Gravesâ€™ orbitopathy during treatment. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 371-378.	3.3	8
13	New Formulations of Levothyroxine in the Treatment of Hypothyroidism: Trick or Treat?. <i>Thyroid</i> , 2021, 31, 193-201.	4.5	43
14	Patient satisfaction and quality of life in hypothyroidism: An online survey by the british thyroid foundation. <i>Clinical Endocrinology</i> , 2021, 94, 513-520.	2.4	53
15	Recent evidence sets therapeutic targets for levothyroxine-treated patients with primary hypothyroidism based on risk of death. <i>European Journal of Endocrinology</i> , 2021, 184, C1-C3.	3.7	10
16	Use of thyroid hormones in hypothyroid and euthyroid patients: A 2020 THESIS questionnaire survey of members of the Danish Endocrine Society. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 2435-2444.	3.3	23
17	Use of thyroid hormones in hypothyroid and euthyroid patients: a THESIS* questionnaire survey of Polish physicians. *THESIS: Treatment of hypothyroidism in Europe by specialists: an international survey. <i>Endokrynologia Polska</i> , 2021, 72, 357-365.	1.0	18
18	Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients: A 2020 THESIS Questionnaire Survey of Members of the Swedish Endocrine Society. <i>Frontiers in Endocrinology</i> , 2021, 12, 795111.	3.5	16

#	ARTICLE	IF	CITATIONS
19	A survey on the psychological impact and access to health care of thyroid patients during the first SARS-CoV-2 lockdown. <i>Clinical Endocrinology</i> , 2021, , .	2.4	9
20	Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients; the 2019 Italian Survey. <i>European Thyroid Journal</i> , 2020, 9, 25-31.	2.4	34
21	A survey of current practices by the British Oculoplastic Surgery Society (BOPSS) and recommendations for delivering a sustainable multidisciplinary approach to thyroid eye disease in the United Kingdom. <i>Eye</i> , 2020, 34, 1662-1671.	2.1	4
22	New Therapeutic Horizons for Graves™ Hyperthyroidism. <i>Endocrine Reviews</i> , 2020, 41, 873-884.	20.1	56
23	Asymmetric Graves™ Orbitopathy. <i>Frontiers in Endocrinology</i> , 2020, 11, 611845.	3.5	9
24	Asymmetry indicates more severe and active disease in Graves™ orbitopathy: results from a prospective cross-sectional multicentre study. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1717-1722.	3.3	15
25	Differentiated thyroid cancer mortality by disease stage in northern England. <i>Clinical Endocrinology</i> , 2020, 93, 61-66.	2.4	2
26	Weight gain following treatment of hyperthyroidism™A forgotten tale. <i>Clinical Obesity</i> , 2019, 9, e12328.	2.0	34
27	Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves' Hyperthyroidism: A Phase I Study. <i>Thyroid</i> , 2019, 29, 1003-1011.	4.5	72
28	Clinical Presentation and Outcomes of Pheochromocytomas/Paragangliomas in Neurofibromatosis Type 1. <i>European Endocrinology</i> , 2019, 15, 95.	1.5	19
29	Predictive score for the development or progression of Graves™ orbitopathy in patients with newly diagnosed Graves™ hyperthyroidism. <i>European Journal of Endocrinology</i> , 2018, 178, 635-643.	3.7	59
30	Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 287-298.	11.4	128
31	Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. <i>Endocrine-Related Cancer</i> , 2018, 25, 309-322.	3.1	103
32	Efficacy and safety of telotristat ethyl (TE) in combination with lanreotide (LAN) in patients with a neuroendocrine tumour and carcinoid syndrome (CS) diarrhoea (CSD): Meta-analysis of phase III double-blind placebo (PBO)-controlled TELESTAR and TELECAST studies. <i>Annals of Oncology</i> , 2018, 29, viii470-viii471.	1.2	1
33	The UK Evidence-Based Guidelines for the Management of Thyroid Cancer: Key Recommendations. , 2018, , 7-15.		1
34	A decade of thyroidology. <i>Hormones</i> , 2018, 17, 491-495.	1.9	3
35	A British Ophthalmological Surveillance Unit (BOSU) study into dysthyroid optic neuropathy in the United Kingdom. <i>Eye</i> , 2018, 32, 1555-1562.	2.1	26
36	Pheochromocytomas/paragangliomas and adverse clinical outcomes in patients with Neurofibromatosis type 1. <i>Endocrine Connections</i> , 2018, 7, R254-R259.	1.9	7

#	ARTICLE	IF	CITATIONS
37	Assessment of normal reference values for thyroid uptake of technetium-99m pertechnetate in a single centre UK population. <i>Nuclear Medicine Communications</i> , 2018, 39, 834-838.	1.1	15
38	Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves' orbitopathy?. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 547-553.	3.3	57
39	Tremelimumab-Induced Graves Hyperthyroidism. <i>European Thyroid Journal</i> , 2017, 6, 167-170.	2.4	42
40	Management of thyroid eye disease in the United Kingdom: A multi-centre thyroid eye disease audit. <i>Orbit</i> , 2017, 36, 159-169.	0.8	11
41	Improving the prehospital safety of steroid-dependent patients in northern England: A hospital-initiated ambulance service registration pathway. <i>Clinical Endocrinology</i> , 2017, 87, 881-882.	2.4	2
42	Raising awareness of Graves' orbitopathy with early warning cards. <i>Clinical Endocrinology</i> , 2017, 87, 853-859.	2.4	3
43	Novel Immunomodulatory Treatment Modalities. , 2017, , 177-192.		0
44	The Amsterdam Declaration on Graves' Orbitopathy. , 2017, , 338-344.		1
45	Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 72.	2.7	113
46	Management of primary hypothyroidism: statement by the British Thyroid Association Executive Committee. <i>Clinical Endocrinology</i> , 2016, 84, 799-808.	2.4	149
47	Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines. <i>Journal of Laryngology and Otology</i> , 2016, 130, S150-S160.	0.8	184
48	The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. <i>European Thyroid Journal</i> , 2016, 5, 9-26.	2.4	738
49	Serum thyroglobulin in the monitoring of differentiated thyroid cancer. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, S119-S123.	1.2	14
50	Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study. <i>Digestive and Liver Disease</i> , 2016, 48, 552-558.	0.9	44
51	Hypothyroxinemia, Hyperthyrotropinemia, and Radioiodine: Partners in Crime Against Graves Orbitopathy?. <i>AACE Clinical Case Reports</i> , 2015, 1, e145-e146.	1.1	0
52	Metastatic Midgut Carcinoid in the Myocardium. <i>Clinical Nuclear Medicine</i> , 2015, 40, e446-e447.	1.3	1
53	Diagnosis of Graves' Orbitopathy (DiaGO): Results of a Pilot Study to Assess the Utility of an Office Tool for Practicing Endocrinologists. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E458-E462.	3.6	11
54	The role of colonoscopic screening in acromegaly revisited: review of current literature and practice guidelines. <i>Pituitary</i> , 2015, 18, 568-574.	2.9	40

#	ARTICLE	IF	CITATIONS
55	Management of patients with Graves' orbitopathy: initial assessment, management outside specialised centres and referral pathways. <i>Clinical Medicine</i> , 2015, 15, 173-178.	1.9	33
56	PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. <i>British Journal of Ophthalmology</i> , 2015, 99, 1531-1535.	3.9	92
57	Future Research in Graves' Orbitopathy: From Priority Setting to Trial Design Through Patient and Public Involvement. <i>Thyroid</i> , 2015, 25, 1181-1184.	4.5	8
58	Thyroglobulin in differentiated thyroid cancer. <i>Clinica Chimica Acta</i> , 2015, 444, 310-317.	1.1	24
59	Medical Management of Mild and Moderate to Severe Thyroid Eye Disease. , 2015, , 83-88.		0
60	Saving lives of inpatients with adrenal insufficiency: implementation of an alert scheme within the Newcastle-upon-Tyne Hospitals ePrescribing platform. <i>Clinical Endocrinology</i> , 2014, 81, 937-938.	2.4	7
61	Pilot of BRAF mutation analysis in indeterminate, suspicious and malignant thyroid FNA cytology. <i>Cytopathology</i> , 2014, 25, 146-154.	0.7	37
62	Novel Thermal Imaging Analysis Technique for Detecting Inflammation in Thyroid Eye Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4600-4606.	3.6	20
63	Patient Knowledge of Antithyroid Drug-Induced Agranulocytosis. <i>European Thyroid Journal</i> , 2014, 3, 245-251.	2.4	20
64	Residual Adrenal Function in Autoimmune Addison's Disease: Improvement After Tetracosactide (ACTH ₁₋₂₄) Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 111-118.	3.6	31
65	Guidelines for the management of thyroid cancer. <i>Clinical Endocrinology</i> , 2014, 81, 1-122.	2.4	961
66	Lanreotide autogel/depot (LAN) treatment for carcinoid syndrome (CS) symptoms: Patient-reported outcomes (PROs) from the SYMNET study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4111-4111.	1.6	0
67	The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves' orbitopathy. <i>Clinical Endocrinology</i> , 2013, 79, 437-442.	2.4	64
68	Is Recombinant Human TSH a Trigger for Graves' Orbitopathy?. <i>European Thyroid Journal</i> , 2012, 1, 105-109.	2.4	9
69	European Thyroid Association Guidelines on L-T4 + L-T3 Combination for Hypothyroidism: A Weary Step in the Right Direction. <i>European Thyroid Journal</i> , 2012, 1, 51-54.	2.4	16
70	An Unusual Presenting Symptom of Graves' Disease: Myalgia. <i>European Thyroid Journal</i> , 2012, 1, 274-6.	2.4	2
71	Orbital decompression for Graves' orbitopathy in England. <i>Eye</i> , 2012, 26, 434-437.	2.1	6
72	Management plan and delivery of care in Graves' ophthalmopathy patients. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2012, 26, 303-311.	4.7	7

#	ARTICLE	IF	CITATIONS
73	Carcinoid Tumour in an Ileocystoplasty: A Reminder to Consider Native Bowel Disease in the Reconstructed Urinary Tract. <i>British Journal of Medical and Surgical Urology</i> , 2011, 4, 39-41.	0.2	2
74	Rising Serum 25-Hydroxyvitamin D Levels After Weight Loss in Obese Women Correlate With Improvement in Insulin Resistance. <i>Obstetrical and Gynecological Survey</i> , 2011, 66, 23-24.	0.4	0
75	Clinical Spectrum of Graves Orbitopathy. <i>Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry</i> , 2011, 11, 83-89.	0.5	0
76	2009 American Thyroid Association Guidelines on Thyroid Nodules. <i>Clinical Oncology</i> , 2010, 22, 469-471.	1.4	6
77	Metachronous testicular teratoma, testicular seminoma and papillary thyroid carcinoma occurring in a single individual: a report of two unrelated cases. <i>European Journal of Cancer Care</i> , 2010, 19, 701-702.	1.5	1
78	General Management Plan. , 2010, , 88-95.		0
79	Rising Serum 25-Hydroxy-Vitamin D Levels after Weight Loss in Obese Women Correlate with Improvement in Insulin Resistance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 4251-4257.	3.6	140
80	The Amsterdam Declaration on Graves' Orbitopathy. <i>Thyroid</i> , 2010, 20, 245-246.	4.5	30
81	The Amsterdam Declaration on Graves'™ Orbitopathy. , 2010, , 265-270.		0
82	The patient experience of services for thyroid eye disease in the United Kingdom: results of a nationwide survey. <i>European Journal of Endocrinology</i> , 2009, 161, 483-487.	3.7	51
83	The Management of Hypogonadism in Aging Male Patients. <i>Postgraduate Medicine</i> , 2009, 121, 113-121.	2.0	5
84	SDHB-associated renal oncocytoma suggests a broadening of the renal phenotype in hereditary paragangliomatosis. <i>Familial Cancer</i> , 2009, 8, 257-260.	1.9	61
85	Graves orbitopathy: a perspective. <i>Nature Reviews Endocrinology</i> , 2009, 5, 312-318.	9.6	13
86	Thyroid-Associated Orbitopathy: Who and How to Treat. <i>Endocrinology and Metabolism Clinics of North America</i> , 2009, 38, 373-388.	3.2	25
87	Thyroid eye disease. <i>BMJ: British Medical Journal</i> , 2009, 338, b560-b560.	2.3	71
88	Management of Graves'™ orbitopathy in Latin America: an international questionnaire study compared with Europe. <i>Clinical Endocrinology</i> , 2008, 69, 951-956.	2.4	16
89	Use of Somatostatin Analogues in Obesity. <i>Drugs</i> , 2008, 68, 1963-1973.	10.9	28
90	Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. <i>European Journal of Endocrinology</i> , 2008, 158, 273-285.	3.7	611

#	ARTICLE	IF	CITATIONS
91	Declaraci3n de consenso del Grupo europeo sobre la orbitopat4a de Graves (EUGOGO) sobre el tratamiento de la orbitopat4a de Graves (OG). Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2008, 55, 356.e1-356.e13.	0.8	0
92	Erectile Dysfunction in Patients with Hyper- and Hypothyroidism: How Common and Should We Treat?. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1815-1819.	3.6	103
93	Thyroid autoimmunity, infertility and miscarriage. Expert Review of Endocrinology and Metabolism, 2008, 3, 127-136.	2.4	15
94	Mortality from thyroid cancer in patients with hyperthyroidism: the Theagenion Cancer Hospital experience. European Journal of Endocrinology, 2008, 159, 799-803.	3.7	41
95	Consensus Statement of the European Group on Graves' Orbitopathy (EUGOGO) on Management of Graves' Orbitopathy. Thyroid, 2008, 18, 333-346.	4.5	342
96	Detection of Hurthle Cell Carcinoma Using Sestamibi. Thyroid, 2008, 18, 575-576.	4.5	4
97	Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey. British Journal of Ophthalmology, 2007, 91, 455-458.	3.9	253
98	A Patient with Asymmetric Parotid Uptake on a Diagnostic Iodine-131 Scan during Thyroid Cancer Follow-Up. Thyroid, 2007, 17, 801-802.	4.5	2
99	A 52-Year-Old Female with a Hoarse Voice and Tingling in the Hand. PLoS Medicine, 2007, 4, e29.	8.4	0
100	Milk alkali syndrome without the milk. BMJ: British Medical Journal, 2007, 335, 397-398.	2.3	12
101	Psychological implications of Graves's™ orbitopathy. European Journal of Endocrinology, 2007, 157, 127-131.	3.7	95
102	Genomic Polymorphism at the Interferon-Induced Helicase (IFIH1) Locus Contributes to Graves's™ Disease Susceptibility. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3338-3341.	3.6	104
103	Introduction to the updated guidelines on the management of thyroid cancer. Clinical Medicine, 2007, 7, 321-322.	1.9	18
104	General Management Plan. , 2007, , 88-95.		9
105	Plasma endothelin response to acute hypoglycaemia in adults with Type 1 diabetes. Diabetic Medicine, 2007, 24, 1039-1042.	2.3	22
106	Fatal inflammatory hypophysitis. Pituitary, 2007, 10, 107-111.	2.9	27
107	Prevention of thyroid associated-ophthalmopathy in children and adults: current views and management of preventable risk factors. Pediatric Endocrinology Reviews, 2007, 4, 218-24.	1.2	10
108	A questionnaire survey on the management of Graves's™ orbitopathy in Europe. European Journal of Endocrinology, 2006, 155, 207-211.	3.7	68

#	ARTICLE	IF	CITATIONS
109	Phaeochromocytomas presenting as acute crises after beta blockade therapy. <i>Clinical Endocrinology</i> , 2006, 65, 186-190.	2.4	82
110	Cushing's syndrome without excess cortisol. <i>BMJ: British Medical Journal</i> , 2006, 332, 469-470.	2.3	18
111	What is the evidence behind the evidence-base? The premature death of block-replace antithyroid drug regimens for Graves's disease. <i>European Journal of Endocrinology</i> , 2006, 154, 783-786.	3.7	44
112	Clinical assessment of patients with Graves's orbitopathy: the European Group on Graves's Orbitopathy recommendations to generalists, specialists and clinical researchers. <i>European Journal of Endocrinology</i> , 2006, 155, 387-389.	3.7	247
113	Thyrotoxicosis and Pregnancy. <i>PLoS Medicine</i> , 2005, 2, e370.	8.4	2
114	A 69-Year-Old Female with Tiredness and a Persistent Tan. <i>PLoS Medicine</i> , 2005, 2, e229.	8.4	0
115	rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. <i>Endocrine-Related Cancer</i> , 2005, 12, 49-64.	3.1	154
116	A Prospective Study of the Effects of Radioiodine Therapy for Hyperthyroidism in Patients with Minimally Active Graves's Ophthalmopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5321-5323.	3.6	139
117	Early Response to Intravenous Glucocorticoids for Severe Thyroid-Associated Ophthalmopathy Predicts Treatment Outcome. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2005, 21, 328-336.	1.4	46
118	Influence of an Early-Onset Age of Type 1 Diabetes on Cerebral Structure and Cognitive Function. <i>Diabetes Care</i> , 2005, 28, 1431-1437.	8.6	208
119	Analysis of Peripheral Blood T-Cell Subsets in Active Thyroid-Associated Ophthalmopathy: Absence of Effect of Octreotide-LAR on T-Cell Subsets in Patients with Thyroid-Associated Ophthalmopathy. <i>Thyroid</i> , 2005, 15, 1073-1078.	4.5	5
120	Double-Blind, Placebo-Controlled Trial of Octreotide Long-Acting Repeatable (LAR) in Thyroid-Associated Ophthalmopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 5910-5915.	3.6	81
121	Role of the CD40 Locus in Graves' Disease. <i>Thyroid</i> , 2004, 14, 506-509.	4.5	55
122	Serum Thyrotropin is a Better Predictor of Future Thyroid Dysfunction Than Thyroid Autoantibody Status in Biochemically Euthyroid Patients with Diabetes: Implications for Screening. <i>Thyroid</i> , 2004, 14, 853-857.	4.5	31
123	The Codon 620 Tryptophan Allele of the Lymphoid Tyrosine Phosphatase (LYP) Gene Is a Major Determinant of Graves's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 5862-5865.	3.6	416
124	Pituitary Apoplexy: A Review of Clinical Presentation, Management and Outcome in 45 Cases. <i>Pituitary</i> , 2004, 7, 157-163.	2.9	268
125	A New Assay for Thyrotropin Receptor Autoantibodies. <i>Thyroid</i> , 2004, 14, 830-835.	4.5	95
126	A New Assay for Thyrotropin Receptor Autoantibodies. <i>Thyroid</i> , 2004, 14, 830-835.	4.5	78

#	ARTICLE	IF	CITATIONS
127	Multiple endocrine neoplasia type 2A. <i>Cancer Genetics and Cytogenetics</i> , 2003, 141, 157-159.	1.0	13
128	Discordant serum thyroglobulin results generated by two classes of assay in patients with thyroid carcinoma. <i>Cancer</i> , 2003, 98, 41-47.	4.1	31
129	CTLA4 gene and Graves' disease: association of Graves' disease with the CTLA4 exon 1 and intron 1 polymorphisms, but not with the promoter polymorphism. <i>Clinical Endocrinology</i> , 2003, 58, 732-735.	2.4	60
130	Role of serum thyroglobulin measurement in patients with thyroid nodules. <i>Clinical Endocrinology</i> , 2003, 59, 657-657.	2.4	1
131	The Impact of Clinical Guidelines on Surgical Management in Patients with Thyroid Cancer. <i>Clinical Oncology</i> , 2003, 15, 485-489.	1.4	11
132	Thyroid disease and male reproductive function. <i>Journal of Endocrinological Investigation</i> , 2003, 26, 372-380.	3.3	50
133	Radioiodine Uptake in Normal Female Breasts and Liver of a Patient with Differentiated Thyroid Cancer Imaged by Whole Body Scanning. <i>Thyroid</i> , 2003, 13, 511-511.	4.5	5
134	Cognitive Ability and Brain Structure in Type 1 Diabetes. <i>Diabetes</i> , 2003, 52, 149-156.	0.6	270
135	Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience. <i>European Journal of Endocrinology</i> , 2003, 148, 491-495.	3.7	187
136	Apolipoprotein-E Influences Aspects of Intellectual Ability in Type 1 Diabetes. <i>Diabetes</i> , 2003, 52, 145-148.	0.6	23
137	Glucocorticoids in the medical management of Graves' ophthalmopathy. <i>Minerva Endocrinologica</i> , 2003, 28, 223-31.	1.8	4
138	Medical Treatment for Thyroid-Associated Ophthalmopathy. <i>Thyroid</i> , 2002, 12, 241-244.	4.5	12
139	Orbital irradiation for thyroid-associated orbitopathy: conventional dose, low dose or no dose?. <i>Clinical Endocrinology</i> , 2002, 56, 689-691.	2.4	10
140	Management of recurrent pituitary cysts with pituitary-nasal drain. <i>Pituitary</i> , 2002, 5, 225-233.	2.9	6
141	Management of a pregnant patient with Graves' disease complicated by thionamide-induced neutropenia in the first trimester. <i>Clinical Endocrinology</i> , 2001, 54, 559-561.	2.4	17
142	Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. <i>Clinical Endocrinology</i> , 2001, 55, 283-303.	2.4	160
143	Serum S-100 β protein as a biochemical marker for cerebral oedema complicating severe diabetic ketoacidosis. <i>Diabetic Medicine</i> , 2001, 18, 1008-1008.	2.3	2
144	Lesson of the week: Deterioration of symptoms after start of thyroid hormone replacement. <i>BMJ: British Medical Journal</i> , 2001, 323, 332-333.	2.3	36

#	ARTICLE	IF	CITATIONS
145	Evidence for a Graves' Disease Susceptibility Locus at Chromosome Xp11 in a United Kingdom Population. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 626-630.	3.6	54
146	Evidence for a Graves' Disease Susceptibility Locus at Chromosome Xp11 in a United Kingdom Population. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 626-630.	3.6	54
147	Clinical Presentation and Natural History of Graves' Ophthalmopathy. <i>Growth Hormone</i> , 2001, , 119-136.	0.2	2
148	Elevated serum growth hormone in a patient with Type 1 diabetes: a diagnostic dilemma. <i>Diabetes/Metabolism Research and Reviews</i> , 2000, 16, 211-216.	4.0	17
149	Evaluation of an on-call diabetes service in a large teaching hospital. <i>Diabetic Medicine</i> , 2000, 17, 386-389.	2.3	4
150	Serum S-100beta protein is a potential biochemical marker for cerebral oedema complicating severe diabetic ketoacidosis. <i>Diabetic Medicine</i> , 2000, 17, 807-809.	2.3	25
151	Prevalence of pernicious anaemia in patients with Type 1 diabetes mellitus and autoimmune thyroid disease. <i>Diabetic Medicine</i> , 2000, 17, 749-751.	2.3	49
152	Anti-thyroid drug treatment before radioiodine in patients with Graves' disease: soother or menace?. <i>Clinical Endocrinology</i> , 2000, 53, 1-2.	2.4	12
153	Lack of Antigenicity of Recombinant Human Thyrotropin After Multiple Injections in Patients with Differentiated Thyroid Cancer. <i>Thyroid</i> , 2000, 10, 623-623.	4.5	8
154	Evidence for a New Graves Disease Susceptibility Locus at Chromosome 18q21. <i>American Journal of Human Genetics</i> , 2000, 66, 1710-1714.	6.2	64
155	Association Analysis of the Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) and Autoimmune Regulator-1 (AIRE-1) Genes in Sporadic Autoimmune Addison's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 688-691.	3.6	73
156	Optimizing the Management of Differentiated Thyroid Cancer. <i>Clinical Oncology</i> , 2000, 12, 363-364.	1.4	5
157	Do diabetes guidelines influence the content of referral letters by general practitioners to a diabetes specialist clinic?. <i>Health Bulletin</i> , 2000, 58, 322-7.	0.1	3
158	The cytotoxic T lymphocyte antigen-4 is a major Graves' disease locus. <i>Human Molecular Genetics</i> , 1999, 8, 1195-1199.	2.9	203
159	Severe Thyroid Eye Disease Associated with Primary Hypothyroidism and Thyroid-Associated Dermopathy. <i>Thyroid</i> , 1999, 9, 1115-1118.	4.5	21
160	Evaluation of serum markers of neuronal damage following severe hypoglycaemia in adults with insulin-treated diabetes mellitus. <i>Diabetes/Metabolism Research and Reviews</i> , 1999, 15, 5-12.	4.0	29
161	Further Evidence for a Susceptibility Locus on Chromosome 20q13.11 in Families with Dominant Transmission of Graves Disease. <i>American Journal of Human Genetics</i> , 1999, 65, 1462-1465.	6.2	53
162	Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism confers susceptibility to thyroid associated orbitopathy. <i>Lancet, The</i> , 1999, 354, 743-744.	13.7	119

#	ARTICLE	IF	CITATIONS
163	Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience. <i>Journal of Endocrinological Investigation</i> , 1999, 22, 30-4.	3.3	12
164	Factors influencing preference of insulin regimen in people with type 1 (insulin-dependent) diabetes. <i>Diabetes Research and Clinical Practice</i> , 1998, 39, 23-29.	2.8	15
165	Natural History of Thyroid Eye Disease. <i>Thyroid</i> , 1998, 8, 423-425.	4.5	81
166	Clinical Presentation of Thyroid Associated Orbitopathy. <i>Thyroid</i> , 1998, 8, 427-428.	4.5	51
167	The Long-Term Sequelae of Severe Hypoglycemia on the Brain in Insulin-Dependent Diabetes Mellitus. <i>Hormone and Metabolic Research</i> , 1997, 29, 197-202.	1.5	25
168	Brain Abnormalities Demonstrated by Magnetic Resonance Imaging in Adult IDDM Patients With and Without a History of Recurrent Severe Hypoglycemia. <i>Diabetes Care</i> , 1997, 20, 1013-1018.	8.6	130
169	Hospital management of diabetic ketoacidosis: are clinical guidelines implemented effectively?. , 1997, 14, 482-486.		53
170	An Audit of Waiting Times in the Diabetic Outpatient Clinic: Role of Patients' Punctuality and Level of Medical Staffing. <i>Diabetic Medicine</i> , 1996, 13, 669-673.	2.3	15
171	Non-islet cell tumour-associated hypoglycaemia: 111 In-octreotide imaging and efficacy of octreotide, growth hormone and glucocorticosteroids. <i>Clinical Endocrinology</i> , 1996, 44, 727-731.	2.4	54
172	Altered Taste Sensation in Newly-Diagnosed NIDDM. <i>Diabetes Care</i> , 1996, 19, 768-770.	8.6	76
173	Natural history of thyroid associated ophthalmopathy. <i>Clinical Endocrinology</i> , 1995, 42, 45-50.	2.4	196
174	Frequency of Thyroid Dysfunction in Diabetic Patients: Value of Annual Screening. <i>Diabetic Medicine</i> , 1995, 12, 622-627.	2.3	312
175	Thyroid-associated ophthalmopathy: pathogenesis and clinical management. <i>Bailliere's Clinical Endocrinology and Metabolism</i> , 1995, 9, 115-135.	1.0	40
176	Chronic Pontine Dysfunction Following Insulin-Induced Hypoglycemia in an IDDM Patient. <i>Diabetes Care</i> , 1994, 17, 725-727.	8.6	20
177	Anti-mitochondrial antibodies in patients with Graves' disease may not signify primary biliary cirrhosis.. <i>Postgraduate Medical Journal</i> , 1994, 70, 17-18.	1.8	1
178	Demonstration of thyrotropin binding sites in orbital connective tissue: Possible role in the pathogenesis of thyroid-associated ophthalmopathy. <i>Journal of Endocrinological Investigation</i> , 1994, 17, 163-170.	3.3	40
179	Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic. <i>Clinical Endocrinology</i> , 1993, 38, 367-372.	2.4	218
180	Pathogenesis of thyroid-associated ophthalmopathy. <i>Trends in Endocrinology and Metabolism</i> , 1993, 4, 270-275.	7.1	16

#	ARTICLE	IF	CITATIONS
181	Autoantibodies to Igf-1 Binding Sites in Thyroid Associated Ophthalmopathy. Autoimmunity, 1993, 16, 251-257.	2.6	119
182	Antibodies to orbital tissues in thyroid-associated ophthalmopathy. European Journal of Endocrinology, 1992, 126, 137-142.	3.7	10
183	Pathogenetic mechanisms in thyroid-associated ophthalmopathy. Journal of Internal Medicine, 1992, 231, 205-211.	6.0	16
184	Biological activity of autoantibodies from patients with thyroid-associated ophthalmopathy: in vitro effects on porcine extraocular myoblasts. The Quarterly Journal of Medicine, 1992, 84, 691-706.	1.0	8
185	Measurement of cell proliferation by enzyme-linked immunosorbent assay (ELISA) using a monoclonal antibody to bromodeoxyuridine. Cell Proliferation, 1991, 24, 517-523.	5.3	40
186	Azathioprine in the treatment of thyroid-associated ophthalmopathy. European Journal of Endocrinology, 1990, 122, 8-12.	3.7	69
187	The pathogenesis of thyroid-associated ophthalmopathy. Journal of Endocrinology, 1989, 122, 619-624.	2.6	24
188	Psoas abscess due to retroperitoneal tuberculous lymphadenopathy. Tubercle, 1988, 69, 299-301.	0.6	8
189	DIFFERENTIATION OF AUTOIMMUNE OPHTHALMOPATHY FROM GRAVES'S™ HYPERTHYROIDISM BY ANALYSIS OF GENETIC MARKERS. Clinical Endocrinology, 1988, 28, 601-610.	2.4	24
190	Long-Term Effects of Hypoglycaemia on Cognitive Function and the Brain in Diabetes. , 0, , 285-307.		4
191	Adrenal Cortical Carcinoma. , 0, , 137-141.		0